SEC Form 4 · accession 0001708138-18-000017
REGENERON PHARMACEUTICALS, INC. · REGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael S Brown
Director
Period of report
Aug 22, 2018
Accepted (ET)
Aug 23, 2018 · 4:01 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000872589
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 22, 2018 | M | 1,500 | $177.82 | A | 1,500 | D | |
| Common Stock | Aug 22, 2018 | S | 1,500 | $380.49 | D | 0 | D | |
| Common StockF1 | Mar 19, 2018 | G | 5,000 | $0.00 | A | 5,000 | I | by SLAT |
| Common Stock | Mar 19, 2018 | G | 5,000 | $0.00 | D | 12,349 | I | by Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F2 | $177.82 | Aug 22, 2018 | M | 1,500 | D | — | Jan 2, 2023 | Common Stock | 1,500 | 0 | D |
Explanation of responses
- F1These shares are held in a trust for the benefit of the reporting person's immediate family members. The reporting person's spouse is trustee of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
- F2The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.